Revenue Growth Benchmarks
Top-line performance metrics of companies across industries and countries
Global Big Pharma (Revenue > $5 Bn)
US companies led growth, closely followed by European companies. A minimal number of companies experienced negative growth during this period. The remarkable performance of the sector can be attributed to the global pandemic leading to increased demand for medications and vaccines.
[ 1: LTM Sales in USD Biliion | Red Shading: Companies with negative growth in period | Green Shading: Top 10 companies by growth rank in period ]
| Company | HQ | Reported | Latest | LTM | year-on-year % | CAGR | Growth Rank | ||||||||||||
| Currency | FQ | Sales1 | 3m | 6m | 9m | ltm | 1y | 2y | 3y | 5y | 6m | LTM | 3ycagr | 5ycagr | |||||
| Johnson & Johnson | USA | USD | 2023-12 | 93.02 | 7.3% | 7.0% | 6.8% | 6.5% | 6.5% | 4.0% | 1.0% | 0.9% | 9 | 10 | 27 | 26 | |||
| Roche Holding AG | CHE | CHF | 2023-12 | 67.13 | na | -6.5% | na | -8.2% | -8.2% | -1.9% | 1.2% | 1.2% | 26 | 27 | 26 | 24 | |||
| Merck & Co Inc | USA | USD | 2023-12 | 60.11 | 5.8% | 6.3% | 5.2% | 1.4% | 1.4% | 11.1% | 13.1% | 7.3% | 12 | 17 | 8 | 16 | |||
| Pfizer Inc | USA | USD | 2023-12 | 58.50 | -41.3% | -41.4% | -46.1% | -41.7% | -41.7% | -15.2% | 12.0% | 7.5% | 28 | 28 | 10 | 15 | |||
| AbbVie Inc | USA | USD | 2023-12 | 54.32 | -5.4% | -5.7% | -5.4% | -6.4% | -6.4% | -1.7% | 5.8% | 10.6% | 25 | 26 | 18 | 10 | |||
| Bayer AG | DEU | EUR | 2023-12 | 51.52 | -1.2% | -4.6% | -7.9% | -6.1% | -6.1% | 4.0% | 4.8% | 5.3% | 24 | 25 | 20 | 19 | |||
| Novartis AG | CHE | CHF | 2023-12 | 50.91 | -0.3% | 1.7% | 0.6% | 1.1% | -0.3% | -0.2% | -3.1% | -2.5% | 16 | 19 | 29 | 28 | |||
| Sanofi SA | FRA | EUR | 2023-12 | 50.23 | na | 1.2% | na | 2.3% | 2.3% | 8.9% | 7.5% | 5.4% | 17 | 14 | 15 | 18 | |||
| AstraZeneca PLC | GBR | GBP | 2023-12 | 45.75 | 3.2% | -0.6% | 0.7% | 1.4% | -0.6% | 13.4% | 22.3% | 15.7% | 18 | 18 | 3 | 6 | |||
| Bristol-Myers Squibb Co | USA | USD | 2023-12 | 45.01 | 0.6% | -0.8% | -2.4% | -2.5% | -2.5% | -1.5% | 1.9% | 14.8% | 19 | 22 | 25 | 7 | |||
| GSK PLC | GBR | GBP | 2023-12 | 37.71 | 9.2% | 6.5% | 5.6% | 3.4% | 3.4% | 10.8% | 7.6% | -0.3% | 11 | 13 | 14 | 27 | |||
| Eli Lilly and Co | USA | USD | 2023-12 | 34.12 | 28.1% | 32.4% | 31.0% | 19.6% | 19.6% | 9.8% | 11.6% | 9.7% | 2 | 4 | 11 | 11 | |||
| Novo Nordisk A/S | DNK | USD | 2023-12 | 33.62 | 40.7% | 39.8% | 38.2% | 34.5% | 34.9% | 26.0% | 17.9% | 14.8% | 1 | 2 | 4 | 8 | |||
| Takeda Pharmaceutical Co Ltd | JPN | JPY | 2023-12 | 29.75 | 1.3% | 2.6% | 4.6% | 5.7% | 12.8% | 12.2% | 7.0% | 17.9% | 15 | 11 | 17 | 5 | |||
| Amgen Inc | USA | USD | 2023-12 | 28.19 | 19.8% | 11.9% | 10.0% | 7.1% | 7.1% | 4.2% | 3.5% | 3.5% | 5 | 9 | 21 | 22 | |||
| Gilead Sciences Inc | USA | USD | 2023-12 | 27.12 | -3.7% | -1.9% | 0.3% | -0.6% | -0.6% | -0.3% | 3.2% | 4.2% | 20 | 20 | 22 | 21 | |||
| Merck KGaA | DEU | EUR | 2023-09 | 22.90 | -10.9% | -7.9% | -4.9% | -1.6% | 12.9% | 12.6% | 11.2% | 8.9% | 27 | 21 | 12 | 13 | |||
| Viatris Inc | USA | USD | 2023-12 | 15.43 | -1.0% | -2.2% | -3.1% | -5.1% | -5.1% | -7.1% | 8.9% | 6.2% | 22 | 24 | 13 | 17 | |||
| Otsuka Holdings Co Ltd | JPN | JPY | 2023-12 | 14.40 | 14.3% | 16.0% | 15.7% | 16.1% | 16.1% | 16.1% | 12.4% | 9.3% | 3 | 5 | 9 | 12 | |||
| CSL Ltd | AUS | AUD | 2023-12 | 13.90 | na | 13.3% | na | 23.5% | 31.5% | 20.9% | 14.2% | 14.2% | 4 | 3 | 7 | 9 | |||
| Regeneron Pharmaceuticals Inc | USA | USD | 2023-12 | 13.12 | 0.6% | 7.0% | 8.1% | 7.8% | 7.8% | -9.7% | 15.6% | 20.6% | 10 | 8 | 6 | 4 | |||
| Astellas Pharma Inc | JPN | JPY | 2023-12 | 11.01 | 4.9% | 4.0% | 2.1% | 5.1% | 17.2% | 10.2% | 5.3% | 3.2% | 13 | 12 | 19 | 23 | |||
| Vertex Pharmaceuticals Inc | USA | USD | 2023-12 | 9.87 | 9.3% | 7.9% | 9.7% | 10.5% | 10.5% | 14.1% | 16.7% | 26.5% | 8 | 6 | 5 | 3 | |||
| Biogen Inc | USA | USD | 2023-12 | 9.84 | -6.2% | -2.7% | -3.5% | -3.3% | -3.3% | -5.4% | -9.9% | -6.1% | 23 | 23 | 30 | 29 | |||
| Bausch Health Companies Inc | CAN | USD | 2023-12 | 8.76 | 9.8% | 9.6% | 9.8% | 7.8% | 7.8% | 1.9% | 2.9% | 0.9% | 6 | 7 | 23 | 25 | |||
| Grifols SA | ESP | EUR | 2023-12 | 7.29 | 14.8% | 9.2% | 63.1% | 52.0% | 8.7% | 15.6% | 7.3% | 8.0% | 7 | 1 | 16 | 14 | |||
| BioNTech SE | DEU | USD | 2023-09 | 7.04 | -72.1% | -83.3% | -81.9% | -65.0% | -14.5% | 459.0% | 433.6% | 202.1% | 30 | 30 | 1 | 1 | |||
| Moderna Inc | USA | USD | 2023-12 | 6.75 | -45.4% | -45.0% | -62.0% | -64.2% | -64.2% | -38.3% | 191.0% | 123.0% | 29 | 29 | 2 | 2 | |||
| Organon & Co | USA | USD | 2023-12 | 6.26 | 7.6% | 3.1% | 2.6% | 1.4% | 1.4% | -0.3% | -1.4% | -8.5% | 14 | 16 | 28 | 30 | |||
| Eisai Co Ltd | JPN | JPY | 2023-12 | 5.35 | -5.3% | -2.1% | 0.9% | 1.7% | -1.6% | 7.4% | 2.3% | 4.4% | 21 | 15 | 24 | 20 | |||
| Source: Annual Filings, Company Website | |||||||||||||||||||